Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection

Knuschke, Torben; Bayer, Wibke; Rotan, Olga; Sokolova, Viktoriya; Wadwa, Munisch; Kirschning, Carsten J.; Hansen, Wiebke; Dittmer, Ulf; Epple, Matthias; Buer, Jan; Westendorf, Astrid M.

doi:10.1016/j.nano.2014.06.014

Cited by 45 publications

(51 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Knuschke et al used functionalized triple-shell calcium phosphate (CaP) nanoparticles as carriers for toll-like receptor 9 ligand CpG and antigenic peptides to induce a robust immune response and protection from Friend virus-induced splenomegaly and reduction of viral load. 91 This system provided a proof of concept for the development of nanoparticle-based vaccines for retroviral infection. 91 …”

Section: Nanomedicines For Infectious Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Gendelman

Anantharam

Bronich

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

106

View full text Add to dashboard Cite

Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics are immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.

show abstract

Section: Nanomedicines For Infectious Diseasesmentioning

confidence: 99%

“…91 This system provided a proof of concept for the development of nanoparticle-based vaccines for retroviral infection. 91 …”

Section: Nanomedicines For Infectious Diseasesmentioning

confidence: 99%

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Gendelman

Anantharam

Bronich

et al. 2015

Nanomedicine: Nanotechnology, Biology and Medicine

106

View full text Add to dashboard Cite

show abstract

“…FV is an immunosuppressive retroviral complex [10] consisting of Friend murine leukemia virus (F-MuLV) and the replication-defective, pathogenic spleen focus forming virus, that causes severe splenomegaly and lethal erythroleukemia in adult mice of susceptible strains, while mice that are genetically resistant to the FV-induced disease develop a persistent infection without overt pathology [11]. Depending on the mouse strain, the FV infection can be a very stringent model for the development of prophylactic vaccines, or for therapeutic interventions such as immunotherapy or therapeutic immunization against an established, chronic infection [12–24]. While the FV infection of mice differs in target cell tropism and pathological mechanisms from human retrovirus infections, like the infection with human immunodeficiency virus or human T cell leukemia virus, it is assumed that basic immunological mechanisms that are responsible for the establishment of a chronic infection, and mechanisms required for virus control and clearance, are very similar for these retrovirus infections [25].…”

Section: Introductionmentioning

confidence: 99%

Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors

Bongard¹,

Lapuente

Windmann³

et al. 2017

Retrovirology

Self Cite

View full text Add to dashboard Cite

BackgroundRetroviral envelope (Env) proteins are known to exhibit immunosuppressive properties, which become apparent not only in retroviral infections, but also in gene-based immunizations using retroviral immunogens, where envelope interferes with the induction of CD8+ T cell responses towards another, simultaneously or subsequently delivered, immunogen.ResultsIn the Friend retrovirus mouse model, immunization with a plasmid encoding the Friend murine leukemia virus (F-MuLV) Leader-Gag protein resulted in induction of a strong GagL85–93-specific CD8+ T cell response, while the response was completely abrogated by co-immunization with an F-MuLV Env-encoding plasmid. In order to overcome this interference of retroviral envelope, we employed plasmids encoding the cytokines interleukin (IL) 1β, IL2, IL12, IL15, IL21, IL28A or granulocyte–macrophage colony-stimulating factor (GM-CSF) as genetic adjuvants. Co-application of plasmids encoding IL2, IL12, IL21, IL28A and especially GM-CSF rescued the induction of GagL85–93-specific CD8+ T cells in mice vaccinated with FV Leader-Gag and Env. Mice that were immunized with plasmids encoding Leader-Gag and Env and the cytokines IL1β, IL12, IL15, IL28A or GM-CSF, but not Leader-Gag and Env without any cytokine, showed significantly reduced viral loads upon a high-dose Friend virus challenge infection.ConclusionsOur data demonstrate the potency of cytokine-encoding vectors as adjuvants and immune modulators in composite vaccines for anti-retroviral immunization.Electronic supplementary materialThe online version of this article (doi:10.1186/s12977-017-0352-7) contains supplementary material, which is available to authorized users.

show abstract

“…CaP nanoparticles have previously been used for efficient delivery of biomaterials in vivo [50,51]. In our study, we used CaP/PLGA nanoparticles to deliver siRNA, protected by PLGA, a biocompatible and biodegradable polymer which is frequently used for the delivery of biopharmaceuticals [52].…”

Section: Discussionmentioning

confidence: 99%

Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo

Frede

Neuhaus

Klopfleisch

et al. 2016

Journal of Controlled Release

Self Cite

107

View full text Add to dashboard Cite

Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection

Cited by 45 publications

References 47 publications

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases

Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors

Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo

Contact Info

Product

Resources

About